<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808300</url>
  </required_header>
  <id_info>
    <org_study_id>UMPT-1</org_study_id>
    <secondary_id>H-1212-030-449</secondary_id>
    <nct_id>NCT01808300</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid.</brief_title>
  <official_title>A Randomized,Open-label,Six-sequence,Three-period,Three-treatment,Multiple Dosing Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid After Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unimed Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unimed Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, six-sequence, three-period, three-treatment, multiple dosing
      clinical trial to investigate the pharmacokinetic drug interaction between Pregabalin and
      Thioctic acid after oral administration in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss / Cmax of pregabalin and thioctic acid</measure>
    <time_frame>2d (9d, 16d): 0h (predose:Thioctic acid), 12h (pre-dose:Pregabalin), 3d(10d, 17d): 0h (pre-dose), 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12h, 24h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ctrough,ss / Tmax,ss / t½ / CL/F of pregabalin and thioctic acid</measure>
    <time_frame>2d (9d, 16d): 0h (predose:Thioctic acid), 12h (pre-dose:Pregabalin), 3d(10d, 17d): 0h (pre-dose), 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12h, 24h</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A-B-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to A-B-C sequence for 3 period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-C-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to A-C-B sequence for 3 period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-C-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to B-C-A sequence for 3 period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-A-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to B-A-C sequence for 3 period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-A-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to C-A-B sequence for 3 period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-B-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug will be administered to according to C-B-A sequence for 3 period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 300mg, Thioctic acid 600mg</intervention_name>
    <description>A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days
B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days
C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B</description>
    <arm_group_label>A-B-C</arm_group_label>
    <arm_group_label>A-C-B</arm_group_label>
    <arm_group_label>B-C-A</arm_group_label>
    <arm_group_label>B-A-C</arm_group_label>
    <arm_group_label>C-A-B</arm_group_label>
    <arm_group_label>C-B-A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Body weight ae least 50kg and BMI(body mass index) within the range of 18 to 27kg/m2

          2. Provision of signed written informed consent

          3. Acceptable physical examination and clinical examination, during screening

        Exclusion Criteria:

          1. A subject with clinical evidence or history of hepatic (including carrier of hepatitis
             virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic,
             oncologic, psychiatric, or cardiovascular disease

          2. A subject with a history of gastrointestinal disease or surgery (except simple
             appendectomy or repair of hernia), which can influence the absorption of the study
             drug

          3. A subject with history of allergies including study drug (pregabalin or thioctic acid)
             or other drug allergies (aspirin, antibiotics, etc.), or history of clinically
             significant allergies

          4. A subject whose lab test results are as follows: AST(SGOT), ALT(SGPT) &gt; 1.5 x upper
             limit of reference range

          5. Presence or history of drug abuse or positive result in urine drug screening test

          6. Use any prescriptive medication, Korean traditional medication not considered
             acceptable by the clinical investigator during the last 14 days period before first
             dosing, or use any OTC medication not considered acceptable by the clinical
             investigator during the last 7 days period before first dosing (if used medication is
             considered acceptable by investigator, patients can be included)

          7. Participation in clinical trials of any drug within 60 days prior to the participation
             of the study

          8. Blood donation during 2 months or apheresis during 1 month before the study

          9. Use of alcohol over 21 units/weeks

         10. Smoker who smoke more than 10 cigarettes per day or who cannot stop smoking during the
             study period (from 24 hours before hospitalization to discharge)

         11. Use of caffeine drink during the study period(from 24 hours before hospitalization to
             discharge)

         12. A subject who takes grapefruit, grapefruit juice, or grapefruit-containing products
             during the study

         13. Judged to be inappropriate for the study by the investigator after reviewing clinical
             laboratory results or other reasons.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2013</study_first_submitted>
  <study_first_submitted_qc>March 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <last_update_submitted>August 21, 2013</last_update_submitted>
  <last_update_submitted_qc>August 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

